Core Insights - Indivior Pharmaceuticals Inc. announced a survey revealing significant gaps in the availability of medications for opioid use disorder (MOUD) in U.S. correctional facilities [1][2] Group 1: Survey Findings - The survey, conducted in partnership with the National Commission on Correctional Health Care, included 212 jails, prisons, and detention centers, finding that only 58% offer at least one FDA-approved MOUD [2] - Jails are more than twice as likely to provide MOUD compared to prisons, with facilities in the West having over three-fold higher odds of offering MOUD than those in the Midwest [3] - The South reports the lowest rates of treatment access, with fewer than 10% of diagnosed individuals receiving treatment, while Midwest facilities show moderate levels of treatment, with some below 10% and others between 20%-29% [3] Group 2: Urgency for Change - The study emphasizes the need for integrating evidence-based care into correctional facilities, highlighting that 17% of individuals in state prisons and 19% in jails meet the criteria for opioid use disorder [4] - Individuals in their first two weeks post-release face overdose mortality rates up to 40 times higher than the national average, indicating the critical need for MOUD treatment during incarceration [4] Group 3: Recommendations for Improvement - Respondents identified five key areas for improving MOUD continuity and outcomes, including housing and employment support, which are essential for sustaining recovery [6] - There is a call for greater investment in long-acting injectables and telehealth partnerships to extend care into rural settings [8] - Emphasis on the importance of pre-release planning and providing a warm handoff from incarceration to community-based MOUD services [8] Group 4: Barriers to Implementation - Despite the recognition of MOUD as the standard of care, facilities face barriers such as stigma, abstinence-only philosophies, lack of provider training, limited budgets, and geographic disparities in healthcare infrastructure [9]

Group 1 - Indivior PLC will participate in the Stifel 2025 Healthcare Conference on November 13, 2025, with CEO Joe Ciaffoni and CFO Ryan Preblick hosting meetings and a fireside discussion [1] - The fireside discussion will be publicly available via a live webcast [1] - Indivior focuses on developing medicines for opioid use disorder (OUD) and aims to transform OUD into a recognized chronic disease [1] Group 2 - Indivior is set to report its third quarter 2025 financial results on October 30, 2025, at 7:00 a.m. [2] - The company has published results from a clinical trial in JAMA Network Open, supporting rapid SUBLOCADE® induction to improve retention in OUD treatment [3]